Ivonescimab Chemotherapy NSCLC Progression-Free Survival
here’s a breakdown of the key findings from the provided text regarding the study of ivonescimab plus chemotherapy for lung cancer:
Key Results:
Progression-Free Survival (PFS): Ivonescimab + chemotherapy significantly improved PFS, reducing the risk of disease progression or death by 48% compared to chemotherapy alone (HR 0.52, P<0.001). Median PFS was 6.8 months with ivonescimab vs. 4.4 months with chemotherapy.
Overall Survival (OS): There was a trend towards improved OS with ivonescimab (16.8 months vs. 14.0 months), but this was not statistically notable (HR 0.79, P=0.0570).
Response Rate: The overall response rate was higher in the ivonescimab group (44.7% vs. 34.2%).
Brain Metastases: The benefit of ivonescimab was notably strong in patients with brain metastases (HR 0.34).
Safety: Grade ≥3 treatment-related adverse events were slightly more common with ivonescimab (50.0%) than with chemotherapy alone (42.2%). These were mostly lab abnormalities. VEGF-related side effects (hypertension, proteinuria) were more frequent with ivonescimab but generally manageable. Treatment-related deaths were rare in both groups.
Study Details:
Treatment: Ivonescimab was given in combination with chemotherapy for four cycles, followed by maintenance therapy. Patient Population: A difficult-to-treat patient population with lung cancer. Follow-up: Primary analysis had a median follow-up of 22.3 months, final OS analysis 29.7 months.
* N=345 patients were included in the primary analysis.
In conclusion: Ivonescimab plus chemotherapy appears to be a promising treatment option for lung cancer, offering a significant advancement in progression-free survival and a potential trend towards improved overall survival, with a manageable safety profile. The benefit extends to patients with brain metastases.